This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: M61.1 | Special Copayment Reduction: V224 (rare disease Special Copayment Reduction) |
| B. Synonyms | Fibrodysplasia ossificans progressiva | Myositis ossificans (progressive), FOP, Fibrodysplasia ossificans progressiva, Stone Man Syndrome, Munchmeyer disease |
| C. Adult onset | Likelihood of first onset in adulthood: low — typically presents in infancy to childhood (ages 2–5) with a first flare (episode of heterotopic ossification) in the neck and back. However, rarely, carriers of mild atypical ACVR1 variants remain undiagnosed until adulthood, when the disease is first recognized. |
| 1. History | 1736 first described by Freke → 1869 detailed report by Münchmeyer → 1918 Rosenstirn recognizes association with congenital malformation of the great toe → 2006 discovery of ACVR1/ALK2 gene mutation → 2023 FDA approval of Palovarotene. |
| 2. Causes | Pathogenic c.617G>A (R206H) variant in the ACVR1 (ALK2) gene. Aberrant activation of the BMP (bone morphogenetic protein) signaling pathway causes heterotopic ossification in muscles, tendons, ligaments, and fascia. |
| 3. Genetics | ACVR1 gene (2q23-q24): encodes BMP receptor type 1A. Mostly de novo mutations. Autosomal dominant. R206H variant in about 97%. Atypical ACVR1 variants in a minority (more severe or milder phenotypes). |
| 4. General epidemiology | About 1 per 2 million worldwide. About 900 patients worldwide (officially registered). Equal in males and females. No ethnic predilection. Several dozen estimated in Korea. 100% arise from de novo mutations without family history. |
| 5. Pathophysiology | R206H-variant ACVR1 is constitutively activated even without BMP ligand. Trauma, inflammation, and infection stimuli trigger heterotopic ossification flares. Muscle tissue ossifies via the endochondral ossification pathway. Order of involvement: posterior cervical → shoulders → spine → elbows → hips. |
| 6. Symptoms | Episodic swelling ("flares") of the neck, back, and shoulders in childhood, followed by heterotopic ossification (bone formation outside the skeleton). Short great toe present from birth. Progressive joint fixation, respiratory restriction (with thoracic ossification), jaw locking. |
| 7. Signs | Congenital malformation of the great toe (shortening or valgus). Heterotopic ossification masses in the neck, shoulders, and back. Progressive reduction in joint range of motion. Chest X-ray: heterotopic bone around the spine and ribs. CT: precise identification of the location and extent of heterotopic ossification. ALP may be elevated. |
| 8. Screening | Suspect FOP when a congenital great toe malformation is found. Confirmed by ACVR1 genetic testing. Invasive biopsy is absolutely contraindicated (trauma triggers heterotopic ossification). Radiological studies (hand and foot X-rays, whole-body CT). |
| 9. Diagnosis | Clinical (congenital great toe malformation + childhood heterotopic ossification flares) + ACVR1 molecular genetic testing. Biopsy absolutely contraindicated. Whole-body bone scintigraphy and CT to assess extent of heterotopic ossification. Differentiate from malignant tumors, heterotopic ossification, and osseous myoma. |
| 10. Treatment | Currently no curative treatment (2023 FDA approval of Palovarotene, an RAR-γ agonist, to prevent new heterotopic ossification). Flare management: short-term steroids. Trauma, procedures, and invasive interventions absolutely prohibited. Symptomatic treatment-centered. Genetic counseling. |
| 11. Prognosis | Progressive and poor. Most use a wheelchair by around their 40s. Mean life expectancy about 56 years (pneumonia and respiratory failure due to ossification of respiratory muscles). Early diagnosis and avoidance of trauma are the only ways to slow disease progression. |
| 12. Prevention | Strict avoidance of trauma (falls, injections, procedures, surgery, and dental treatment all trigger flares). Minimize invasive interventions. Vaccination against infections (reduces flare triggers). Long-term Palovarotene. |
| 13. References | Kaplan FS et al. Classical and atypical fibrodysplasia ossificans progressiva … and 9 other references |
Fibrodysplasia ossificans progressiva (FOP) is one of the most dramatic rare diseases in human history, a disease in which a "second skeleton" forms in the body. The first description of FOP in the formal medical literature was made in 1736 by the London surgeon John Freke. Freke described a 14-year-old boy whose spine and ribs were joined by bone and reported that the boy's soft tissues were hardening into bone.
More detailed descriptions were made in the 1800s. In 1869, Ernst Munchmeyer of Germany provided a systematic clinical description of the disease and recognized that it progresses toward bone formation in soft tissues, including muscles, tendons, and ligaments. For this reason, it was also called "Munchmeyer disease" by some. In 1918, Rosenstirn was the first to systematically describe that congenital malformation of the great toe (shortening, valgus) is almost invariably present in patients with FOP, and this finding later became an essential diagnostic criterion for FOP.
In the first half of the 20th century, FOP was often misdiagnosed as cancer, and the tragedy of patients undergoing local excision surgery was repeated. Surgery itself often triggered heterotopic ossification flares, making the disease worse. In the 1950s–60s, researchers led by Kaplan systematically documented the natural history of FOP and the anatomical order of progression of heterotopic ossification (posterior cervical → shoulders → spine → elbows → hips, i.e., in a craniocaudal, proximal-to-distal, and dorsal-to-ventral direction).
The most revolutionary turning point in FOP research came in 2006, when the research team of Frederick Kaplan and Eileen Shore at the University of Pennsylvania in the United States identified the c.617G>A (Arg206His) mutation in ACVR1 (Activin receptor type I, ALK2), the gene responsible for FOP. This discovery revealed that aberrant activation of the BMP (bone morphogenetic protein) signaling pathway is the core mechanism of FOP and subsequently became the basis for developing therapies targeting the BMP pathway. In 2023, the US FDA approved palovarotene (Palovarotene, Sohonos), a retinoic acid receptor gamma (RAR-γ) agonist, as a treatment to prevent heterotopic ossification in patients with FOP aged 8 years or older (females) or 10 years or older (males). This is the first approved disease-modifying therapy for FOP.
FOP research and patient support in Korea have been carried out since the 2000s in connection with the International FOP Association (IFOPA), and the number of patients in Korea is estimated at several dozen. FOP is registered for rare disease Special Copayment Reduction (V224).
The cause of FOP is a pathogenic point mutation in the ACVR1 (Activin receptor type IA, also known as ALK2) gene. This gene is located on chromosome 2 (2q23-q24) and encodes the ALK2 protein, a member of the type I TGF-β receptor family that transmits BMP (bone morphogenetic protein) signals into the cell.
In about 97% of patients with classic FOP, the c.617G>A (R206H) variant is identified, a missense variant in which arginine at position 206 is replaced by histidine. In the remaining approximately 3%, atypical variants at other sites in ACVR1 (L196P, P197S, R202I, Q207E, R258G, R258S, G328W, G328E, G356D, R375P, etc.) are observed. These atypical variants may differ from R206H in age of onset, rate of progression of heterotopic ossification, and phenotypic characteristics.
The ACVR1 protein carrying the R206H variant is constitutively activated (constitutive activation) even without binding of BMP ligand. A receptor that normally requires BMP binding to be activated is, because of the variant, made to continuously send bone-forming signals through ligand-independent phosphorylation of SMAD 1/5/8. This excess signaling activates the small number of osteogenic progenitor cells in soft tissues such as muscles, tendons, ligaments, and fascia, forming heterotopic bone through the endochondral ossification pathway.
Most cases of FOP arise from de novo mutations without a family history, and when a patient passes the gene on, each child has a 50% chance of being affected (autosomal dominant). In addition to germline mutations, a very small number of cases of mosaic mutations have also been reported.
Importantly, in FOP, heterotopic ossification "flare-ups" can be triggered by trauma (bruises, injections, surgery, stretching or ligament injuries), infections (such as viral respiratory infections), or even without apparent cause. When an external stimulus induces an inflammatory response in tissue, this inflammatory signal is understood to further trigger the already hyperactivated ACVR1 pathway, causing a heterotopic ossification flare.
FOP is an autosomal dominant disease caused by heterozygous pathogenic variants in the ACVR1 (ALK2) gene. The ACVR1 gene is located on chromosome 2 (2q23-q24) and consists of 11 exons. The ALK2 (Activin receptor-like kinase 2) protein it encodes consists of 520 amino acids and is a member of the type I TGF-β/BMP receptor kinase family. Normally, when ligands such as BMP2, BMP4, and BMP7 bind, the GS domain (glycine-serine-rich domain) of ALK2 is phosphorylated and activated by type II receptors (BMPR2, ActRII), after which SMAD1/5/8 are phosphorylated and translocate to the nucleus to activate bone formation-related genes.
The R206H variant occurs within the GS domain of ALK2 (amino acid position 206), and this variant releases the autoinhibitory structure of the GS domain, resulting in ligand-independent constitutive activation. An important finding reported since 2015 is that Activin A (Inhibin βA subunit homodimer) acts on normal ALK2 to inhibit BMP signaling but paradoxically acts as an "activating ligand" that sends a strong bone-forming signal through R206H-variant ALK2; accordingly, an antibody that inhibits Activin A (garetosmab) has been evaluated in FOP clinical trials.
Atypical FOP variants show phenotypic differences compared with R206H. For example, the L196P variant may present without great toe malformation and with mild heterotopic ossification, and the G328W variant is associated with the FOP plus phenotype, with more severe cognitive impairment or retinal abnormalities. Research on clinical phenotypes by variant type is ongoing.
Because most FOP arises from de novo mutations, the patient's ACVR1 variant is real even if parental genetic testing is negative. If a patient has children, each child has a 50% chance of inheriting the FOP gene (autosomal dominant). Preimplantation genetic testing (PGT) and prenatal diagnosis are theoretically possible, but because adult life functioning in FOP patients themselves is severely limited, this decision requires ethical and personal consideration.
FOP is one of the rarest diseases in human history and is estimated to occur at a frequency of about 1 per 2 million people worldwide. According to 2024 data from the International FOP Association (IFOPA), the number of officially registered patients worldwide is about 900, but including undiagnosed patients, it is estimated at about 4,000–5,000.
FOP occurs at the same frequency regardless of ethnicity and region, and there is no sex difference (male:female = 1:1). It is unrelated to socioeconomic background, geographic location, or specific environmental factors. This is because FOP arises from de novo mutations in almost all cases. The fact that the same R206H ACVR1 variant is identified in about 97% of FOP patients suggests that the location of this variant is a mutational hotspot that is particularly prone to mutation.
There are no precise epidemiological statistics for Korea, but estimates based on worldwide incidence suggest about 25–30 patients. In Korea, the number of patients registered for rare disease Special Copayment Reduction (V224) is known to be several dozen. Although FOP is extremely rare and its clinical features are distinctive (great toe malformation + childhood heterotopic ossification), lack of physician awareness leads to many cases being misdiagnosed as osteosarcoma, fibrosarcoma, juvenile myositis, and so on, and the fact that diagnosis takes several years on average is a worldwide challenge. The tragedy of biopsies or surgeries performed after misdiagnosis worsening heterotopic ossification is repeated.
In FOP, heterotopic ossification occurs through the same pathway as normal bone formation (endochondral ossification), but it is called heterotopic ossification because it occurs at abnormal sites (muscles, tendons, ligaments, fascia, sinews, etc.). The core molecular mechanism is hyperactivation of the BMP signaling pathway caused by the ACVR1 (R206H) variant.
Constitutive activation of R206H ACVR1: normal ALK2 remains in an inhibited state without BMP ligand, but the R206H variant releases the autoinhibition of the GS domain, so that SMAD1/5/8 signals are sent continuously. Recent research has shown that Activin A acts as a potent activating ligand of R206H-variant ALK2 (in normal ALK2, Activin A inhibits BMP signaling). Accordingly, Activin A secreted during inflammation is attracting attention as a key mechanism that specifically activates R206H ACVR1 and triggers flares.
Activation of osteogenic progenitor cells: the cells receiving the hyperactivated ACVR1 signal are presumed to be mesenchymal progenitor cells present in muscle, such as perivascular cells (pericytes), FAP cells (fibro-adipogenic progenitors), and muscle satellite cells. These cells differentiate into chondroprogenitors under BMP signaling and then form heterotopic bone through the process of endochondral ossification (cartilage → bone).
Inflammation–ossification cascade: FOP flares are induced by various stimuli such as trauma, infection, vaccination, tooth extraction, and surgery. Tissue damage from the stimulus recruits immune cells such as macrophages, mast cells, and T cells, which secrete Activin A, BMP2/4/7, VEGF, and others to initiate heterotopic ossification cascades. Initially it appears as soft tissue swelling and pain (a flare), cartilage forms over several weeks, and calcification and ossification are completed within several months.
Anatomical order of progression: heterotopic ossification typically progresses in a craniocaudal direction (dorsal to ventral, proximal to distal). It begins in the posterior cervical muscles and ligaments and progresses to the shoulders, upper limbs, spine, pelvic girdle, and lower limbs, in that order. This characteristic anatomical pattern of progression is important for clinical recognition of FOP.
The clinical features of FOP are summarized by two main characteristics: ① congenital malformation of the great toe present from birth and ② recurrent heterotopic ossification flares beginning in childhood.
Congenital malformation of the great toe: congenital malformation of both great toes is present in almost all patients with FOP (about 97% or more). The most common form is brachydactyly (the great toe is shorter than normal), often accompanied by valgus deformity. Because this malformation is present from birth, it can be detected at newborn examination. Thumb malformations are also present in some.
Heterotopic ossification flares (Flare-up): the first flare typically begins at ages 2–5. A flare begins with localized swelling, pain, and warmth in the neck, back, or shoulder region and progresses over several weeks. Hard heterotopic bone gradually forms in the swollen area, permanently restricting movement in that area. Flares occur spontaneously and are also triggered after trauma, infection, or invasive procedures. Each flare lasts days to weeks, and a pattern of pain improving after completion of new bone formation is repeated.
Progression of movement restriction: as heterotopic ossification accumulates, joint range of motion gradually decreases. First, neck rotation and flexion become restricted, and then shoulder abduction, elbow flexion and extension, and the spine (scoliosis) become fixed. As ossification of the muscles around the thorax and the intercostal muscles progresses, respiratory function declines (restrictive lung disease). When ossification of the muscles and ligaments around the jaw joint occurs, jaw locking (trismus) makes opening the mouth impossible, making oral intake difficult.
Hearing impairment: progressive conductive hearing loss has been reported in some patients with FOP. This appears to be due to ossification of the ligaments around the middle ear ossicles and heterotopic ossification of structures around the Eustachian tube.
The physical signs of FOP vary by disease stage; early on, the great toe malformation at birth is the only physical finding.
Great toe findings: shortening and valgus deformity of both great toes are the most important findings on physical examination. Radiological examination (foot X-ray) shows abnormalities of the great toe metatarsophalangeal joint and shortening or fusion of the toe bones.
Heterotopic ossification masses: heterotopic ossification sites formed after a flare are palpable as hard, immobile subcutaneous indurations. These indurations can be confused with malignant tumors, but biopsy is absolutely contraindicated because it worsens heterotopic ossification. Masses of heterotopic bone fixed in stages are observed in the neck, shoulders, back, elbows, and elsewhere.
Reduced joint range of motion: restriction of cervical flexion and rotation is an early sign, after which restrictions accumulate in the order of shoulder abduction (difficulty raising the arms to the side), elbow flexion and extension, and hip flexion.
Imaging findings: whole-body X-ray or CT shows heterotopic bone formation distributed along muscles, tendons, and ligaments. 3D CT reconstruction allows the location and extent of heterotopic ossification to be determined precisely. 99mTc-MDP bone scintigraphy shows high uptake at sites of active heterotopic ossification and can be used to monitor flares. MRI is useful for identifying edema and soft tissue changes in early flares.
Laboratory findings: there is no specific serum marker. During active flares, ALP (alkaline phosphatase) elevation and mild ESR and CRP elevation may occur. Bone formation markers (osteocalcin, bone-specific ALP) may increase during active heterotopic ossification. Molecular testing of the ACVR1 gene is the standard for confirmation.
There is no general population screening for FOP. However, the currently recommended early diagnosis strategy is to suspect FOP immediately and perform ACVR1 molecular genetic testing when bilateral great toe shortening or malformation is found at newborn examination.
Clinical screening indicators: ① bilateral great toe shortening and valgus malformation at birth, ② soft tissue swelling of the neck, back, or shoulders with fever in childhood (especially ages 2–10), ③ formation of hard masses in these areas, ④ heterotopic ossification findings on biopsy (histological). Of these four, FOP should be strongly suspected even if only ①+② are present.
Absolute contraindication: invasive biopsy and procedures: in patients with suspected FOP, diagnostic biopsy, surgical excision, and intramuscular injections are absolutely contraindicated. Any form of tissue injury triggers or worsens heterotopic ossification flares. Even when injecting drugs, subcutaneous or intravenous injection rather than intramuscular injection should be used.
Molecular genetic testing: the c.617G>A (R206H) variant of the ACVR1 gene is identified in peripheral blood DNA by PCR-based direct sequencing or next-generation sequencing (NGS). If R206H is negative in an atypical phenotype, whole-gene analysis of ACVR1 is performed. Once molecular confirmation is obtained, unnecessary biopsies and surgeries can be avoided, preventing disease worsening.
Foot X-ray and whole-body CT: foot X-rays and whole-body or regional CT are useful for characterizing the great toe malformation and determining the extent of heterotopic ossification already formed.
FOP is confirmed by the combination of ① characteristic clinical findings and ② ACVR1 molecular genetic testing. Biopsy is never performed.
Clinical diagnostic criteria: FOP is strongly suspected when the following two are present: ① congenital malformation of both great toes (shortening and/or valgus deformity), ② recurrent soft tissue swelling (flares), especially in the neck, back, and shoulders. If both are present, ACVR1 molecular genetic testing is performed immediately.
Molecular genetic confirmation: identification of the c.617G>A (R206H) variant in the ACVR1 gene is the confirmatory criterion. This variant is positive in about 97%. If R206H is negative in an atypical phenotype, whole-gene analysis of ACVR1 (exon sequencing) is performed to identify other pathogenic variants.
Imaging diagnosis: foot and whole-body X-rays and CT identify the great toe malformation and heterotopic ossification. MRI assesses soft tissue inflammation in early flares. PET-CT or bone scintigraphy functionally assesses sites of active flares.
Differential diagnosis: differentiate osteosarcoma and fibrosarcoma (no malignant cells on biopsy, heterotopic ossification confirmed), myositis ossificans progressiva (conceptually a separate disease but the terms are used interchangeably), heterotopic ossification (localized heterotopic ossification after trauma or nerve injury), juvenile dermatomyositis (muscle inflammation findings, elevated CK), and subcutaneous tumors. In FOP, biopsy results usually show fibrotic tissue or immature bone tissue, but because biopsy itself can provoke a devastating flare, clinical and genetic diagnosis should replace biopsy.
Until 2023, treatment of FOP was limited to flare management and symptomatic treatment in the absence of any fundamental disease-modifying therapy. With the FDA approval of palovarotene in 2023, the first disease-modifying treatment option became available, but cure is still not possible.
Palovarotene (Sohonos): a selective retinoic acid receptor gamma (RAR-γ) agonist that inhibits chondrogenic differentiation downstream of BMP/SMAD signaling, preventing heterotopic ossification. In 2023, the US FDA approved it for reducing heterotopic ossification in adult and pediatric patients with FOP aged 8 years or older (females) or 10 years or older (males). A chronic maintenance dose (5 mg/day) and a "flare dose" increased during acute flares (20 mg/day for 4 weeks → 10 mg/day for 8 weeks) are used alternately. The risk of premature epiphyseal closure in growing children is a major adverse effect requiring monitoring.
Absolute prohibition of trauma and invasive procedures: the most important principle in all treatment is to avoid any trauma, invasive procedures, or intramuscular injections. Dental treatment (extraction, implants) can induce heterotopic ossification around the jaw joint, so a conservative approach is taken. Surgery and biopsy are absolutely contraindicated. General anesthesia also carries airway management risks (cervical fixation, limited mouth opening) and requires careful preparation.
Management of acute flares: early administration of corticosteroids (prednisolone 2 mg/kg/day, up to 4 days) is recommended to suppress early flare inflammation and partly reduce heterotopic ossification formation. COX-2 inhibitors may be used as long-term anti-inflammatory therapy, but the evidence is limited. Symptomatic treatment during flares consists of local cold packs, rest, and pain management without intramuscular injections.
Respiratory management: as restrictive lung disease due to thoracic heterotopic ossification progresses, support is provided with noninvasive positive pressure ventilation (CPAP, BiPAP). Prevention of infection (influenza and pneumococcal vaccines) is important for preventing pneumonia.
Other investigational therapies: garetosmab (an anti-Activin A antibody) showed a reduction in heterotopic ossification in a phase 2 clinical trial, but the problem of rebound heterotopic ossification on discontinuation of treatment was identified, and further research is ongoing. Direct ACVR1 inhibitors (small-molecule ALK2 inhibitors) and RNAi-based inhibitors of ACVR1 expression are in preclinical and early clinical stages.
FOP is a progressive disease that cannot yet be cured, and the prognosis is very poor. Disease progression does not stop, and as heterotopic ossification accumulates, the course involves gradual loss of daily functioning and life-sustaining functions.
Functional prognosis: in most patients with FOP, upper limb and spinal movement is already severely restricted by their 20s, and most become wheelchair-dependent in their 30s–40s. When eating becomes difficult because of limited mouth opening (trismus), tube feeding may be needed. Elbow fixation makes personal hygiene and dressing impossible. Some patients unexpectedly maintain considerable function for a long time, which is related to how well flare triggers are avoided.
Life expectancy: in international cohort studies, the median age of survival of patients with FOP is reported to be about 56 years. The main causes of death are restrictive lung disease due to thoracic heterotopic ossification and associated pneumonia (aspiration or infectious). Complications due to limited mouth opening and difficult airway management are also important risk factors for death.
Effect of palovarotene on long-term prognosis: in the phase 3 clinical trial of palovarotene (MOVE trial), a reduction of about 57% in new heterotopic ossification formation was reported. In the long term, this drug is expected to contribute to preservation of function and extension of life expectancy, but long-term outcome data are limited to date.
Primary prevention of FOP is currently not possible. In most cases arising from de novo mutations, there is no means of prevention. The prevention strategy in patients already confirmed is to minimize heterotopic ossification flares.
Strict avoidance of trauma: because any physical trauma can trigger a flare, creating an environment that prevents tripping, prohibiting contact sports, and preventing falls are top priorities. A system that recognizes and protects the special needs of patients with FOP is needed in all settings, including schools, workplaces, and medical institutions.
Minimizing invasive medical procedures: patients should always carry a Medical Alert card so that no health care provider performs intramuscular injections, biopsies, surgery, or tooth extractions on a patient with FOP, and measures should be taken so that this information is communicated even in emergencies. Dental treatment follows a conservative approach in principle (preventive oral hygiene, avoidance of unnecessary procedures).
Infection prevention: because upper respiratory infections trigger flares, vaccinations such as influenza vaccine (annually) and pneumococcal vaccine are kept up to date. COVID-19 vaccination is also recommended.
Long-term palovarotene: palovarotene, approved in 2023, is taken long term in patients meeting the indication to suppress new heterotopic ossification formation. Careful dose adjustment is needed in growing children, considering the risk of growth plate closure.